Clinical Commander

Back to dossier
cardio.hypertensive-emergency.obesity-osa-related.v1PRODUCTION
cardio.hypertensive-emergency.obesity-osa-related.v1

Obesity + obstructive sleep apnea (OSA) hypertensive emergency (resistant-HTN phenotype with sympathetic + RAAS overdrive; CPAP + weight loss + MRA central to long-term control)

cardiologyacuteadult
Hard-required inputs
0 / 13
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Obesity + OSA hypertensive crisis = resistant-HTN phenotype crossed crisis threshold. Pathophys: chronic intermittent hypoxemia + arousals → sympathetic + RAAS + endothelial overdrive; ~30% of resistant HTN explained by OSA. Acute: standard HTN-emergency (nicardipine, labetalol). Specialty value: identify + treat OSA acutely (CPAP) + plan long-term resistant-HTN ladder (MRA + thiazide-like + RDN consideration).

Inputs
4
Actions
0
Advance rule
Set
Advance when

phenotype framed; resistant-HTN + OSA combo confirmed by med list + history

Patient inputs (14)

Confirms OSA + AHI severity (mild 5-15, moderate 15-30, severe ≥30); HSAT acceptable for high pre-test probability; in-lab PSG for complex cases (suspected central apnea, OHS, comorbid arrhythmia) — AASM 2017 PMID 28162150

Obesity + OSA prevalence increases with age until ~70; older patients with OSA + resistant HTN have higher CV event rate

BMI ≥30 defines obesity; ≥40 severe obesity drives bariatric surgery + GLP-1 RA decisions; BMI directly predicts OSA severity (AHI rises with BMI)

Witnessed apnea, loud snoring, daytime sleepiness (Epworth ≥10), morning headache, choking/gasping at night — STOP-BANG ≥3 prompts HSAT/PSG; high pre-test probability for OSA in this phenotype

Resistant HTN definition requires ≥3 agents at max tolerated doses including a diuretic; med-list reconciliation guides PATHWAY-2 ladder + identifies missing MRA/thiazide-like options

Resting hypoxemia (SpO2 <94% at rest) suggests obesity-hypoventilation syndrome (OHS) overlap or severe untreated OSA; nocturnal saturation profiling needed

LVH (Cornell or Sokolow-Lyon criteria) — chronic-pressure-overload signature; right-axis deviation + RAE if cor pulmonale; ischemia/QTc baseline

Demand ischemia rule-out; nocturnal hypoxemia + AM HTN surge can precipitate Type 2 MI in CAD patients

eGFR drives drug dosing; baseline for HTN-related renal injury; CKD + obesity-OSA intersect frequently

LVH + diastolic dysfunction + RV strain (cor pulmonale from chronic OSA) + EF assessment; HFpEF prevalent in obesity-OSA phenotype

Defines crisis threshold; drives titration of nicardipine + labetalol; resistant-HTN-OSA crisis often refractory requiring multi-agent infusion

Component of MAP; DBP >120 supports crisis criterion + diastolic-dominant overload

Sympathetic overdrive from OSA → resting tachycardia; HRV reduced; tachy + LV dysfunction → demand mismatch in CAD

Primary aldosteronism screen — overrepresented in obese + OSA + resistant HTN populations; ARR ≥30 with aldosterone ≥15 suggests PA needing endocrine workup

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationallife_threateningsevere_osa_with_cor_pulmonale_and_rv_failure
    Severe OSA (AHI >30) + cor pulmonale (RV strain on echo) + RV failure presenting with HTN crisis and hypoxemic respiratory failure
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecpap_non_adherence_with_recurrent_htn_crisis
    Patient with documented severe OSA on CPAP but adherence <4 h/night → recurrent HTN crisis events; failure of long-term BP control
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresevere_semaglutide_GI_event_or_pancreatitis
    Severe GI intolerance (intractable nausea/vomiting, dehydration, AKI) OR acute pancreatitis on semaglutide titration → halt drug + supportive care
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverebariatric_surgery_decision_for_BMI_40_refractory_HTN
    Patient with BMI ≥40 and refractory HTN despite 6-12 months maximal medical + lifestyle + CPAP therapy → bariatric surgery evaluation
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENTrequiredDrives monitoring threshold
Loading…

Recommended regimen

Obesity + OSA HTN crisis — acute IV nicardipine + labetalol; CPAP/BiPAP initiation; long-term PATHWAY-2 ladder (MRA + thiazide-like) + GLP-1 RA + bariatric surgery + renal denervation as adjunct
axis: obesity_osa_resistant_htn_crisis_pharmacology
Selected axis "Obesity + OSA HTN crisis — acute IV nicardipine + labetalol; CPAP/BiPAP initiation; long-term PATHWAY-2 ladder (MRA + thiazide-like) + GLP-1 RA + bariatric surgery + renal denervation as adjunct" by default fallback (first axis)
  • nicardipine
    first line
    dihydropyridine_ccb
    5 mg/h IV titrate q5-15 min by 2.5 mg/h, max 15 mg/h • IV • continuous infusion
    triggers: htn_emergency_no_dissection_no_pregnancy
    AHA 2025 HTN emergency Class I — first-line non-dissection adult HTN crisis; predictable titration, minimal reflex tachycardia
    rxcui 7396
  • labetalol
    first line
    mixed_alpha_beta_blocker
    10-20 mg IV q10 min titrate to SBP <160 (max 300 mg cumulative); OR 0.5-2 mg/min infusion • IV • PRN bolus or continuous
    triggers: htn_emergency_with_sympathetic_overdrive, pregnancy_HTN
    AHA 2025 — mixed α/β useful in OSA-driven sympathetic crisis; addresses both vasoconstriction and tachycardia
    rxcui 6185
  • nitroglycerin
    second line
    organic_nitrate
    5-200 mcg/min IV titrate q3-5 min • IV • continuous
    triggers: flash_pulmonary_edema_overlay, concurrent_chest_pain
    Vasodilator + venodilator + coronary vasodilator; useful when LV-failure/pulm-edema overlay present (common in obesity-OSA HFpEF)
    rxcui 4917
  • spironolactone
    first line
    mineralocorticoid_receptor_antagonist
    25 mg PO daily, titrate to 50 mg • PO • daily
    triggers: resistant_HTN_long_term_4th_line
    PATHWAY-2 (Williams Lancet 2015 PMID 26414968) — spironolactone superior to doxazosin and bisoprolol as 4th-line agent for resistant HTN; effect amplified in OSA + PA-enriched populations
    rxcui 9997
  • chlorthalidone
    first line
    thiazide_like_diuretic
    12.5-25 mg PO daily • PO • daily
    triggers: resistant_HTN_baseline_diuretic
    Thiazide-like preferred over HCTZ for resistant HTN (longer half-life, better 24-h BP control); PATHWAY-2 + ALLHAT
    rxcui 2409
  • amlodipine
    first line
    dihydropyridine_ccb
    5-10 mg PO daily • PO • daily
    triggers: htn_baseline_regimen
    CCB pillar of standard 3-drug + MRA resistant-HTN regimen (ACC/AHA 2025)
    rxcui 17767
  • lisinopril
    first line
    ace_inhibitor
    10-40 mg PO daily • PO • daily
    triggers: htn_baseline_regimen
    RAAS-blockade pillar; particularly useful in obesity-OSA where RAAS activation is mechanistic
    rxcui 29046
  • semaglutide
    add on
    glp1_receptor_agonist
    0.25 mg SC weekly × 4 wk → 0.5 mg × 4 wk → 1 mg × 4 wk → 1.7 mg → 2.4 mg SC weekly maintenance • SC • weekly
    triggers: BMI_30_with_obesity_related_HTN, weight_loss_for_HTN_control
    STEP-1 (Wilding NEJM 2021 PMID 33567185) ~15% weight loss; STEP-HFpEF (Kosiborod NEJM 2023 PMID 37877559) cardiometabolic benefit in obesity-related HFpEF; secondary BP reduction via weight loss
    rxcui 1991302
  • tirzepatide
    add on
    dual_gip_glp1_agonist
    2.5 mg SC weekly × 4 wk titrate q4 wk to max 15 mg • SC • weekly
    triggers: BMI_30_with_inadequate_response_to_semaglutide
    SURMOUNT-1 — superior weight loss to semaglutide; BP reduction signal
    rxcui 2601723
  • clonidine
    second line
    central_alpha2_agonist
    0.1 mg PO BID titrate to 0.3 mg BID; transdermal Catapres-TTS-3 0.3 mg/24h alternative • PO + transdermal • BID + weekly patch
    triggers: resistant_HTN_5th_or_6th_line
    Add-on if MRA + α-blocker insufficient; AVOID abrupt discontinuation (rebound HTN risk — cross-link clonidine-withdrawal engine)
    rxcui 2599
  • CPAP / BiPAP for OSA / OHS
    first line
    positive_airway_pressure
    Auto-CPAP 5-15 cmH2O range; titrate to AHI <5 + SpO2 ≥90% across night; BiPAP (IPAP 12-20 / EPAP 6-10) for OHS overlap • mask • every night ≥4 h/night ≥70% of nights
    triggers: confirmed_OSA_AHI_5, OHS_or_severe_OSA_AHI_30
    CRESCENDO (Pedrosa 2014 PMID 24571566) + Schein meta-analysis (PMID 25096531) — CPAP reduces 24-h SBP/DBP by ~7/5 mmHg in resistant HTN with OSA; greatest benefit in severe OSA + adherent users
  • Bariatric surgery (RYGB or sleeve gastrectomy)
    add on
    metabolic_surgery
    Per surgical evaluation • surgical • one-time
    triggers: BMI_40_refractory_HTN_or_BMI_35_with_HTN_target_organ_damage
    Sustained 25-30% weight loss + HTN remission in 50-70%; preferred over medical-only therapy for severe obesity with refractory HTN
  • Renal denervation (RDN)
    add on
    device_based_therapy
    Bilateral renal artery RF or US ablation per SPYRAL/RADIANCE protocol • endovascular • one-time
    triggers: BP_refractory_after_max_medical_therapy_and_lifestyle_and_secondary_causes_excluded
    SPYRAL HTN-OFF MED (Böhm Lancet 2020 PMID 32562445) — sustained ~10/5 mmHg reduction; FDA-approved 2023 for adjunctive use
  • Weight loss + DASH diet + exercise
    first line
    lifestyle_intervention
    Target 5-10% weight loss; DASH diet; 150 min/week moderate aerobic + 2 sessions resistance • lifestyle • daily
    triggers: obesity_BMI_25
    Look AHEAD (Wing NEJM 2013 PMID 23796131) + ACC/AHA 2025 lifestyle recommendation; foundation of all obesity-related HTN management

outpatient playbook — drug actions (3)

  1. 1. maintain PATHWAY-2 ladder
    rxcui 9997
    titrated to BP target • PO • daily
    trigger: sustained maintenance
    ACC/AHA 2025 + PATHWAY-2
  2. 2. maintain semaglutide 2.4 mg
    rxcui 1991302
    2.4 mg SC weekly • SC • weekly
    trigger: sustained weight management
    STEP-1
  3. 3. consider tirzepatide if inadequate semaglutide response
    rxcui 2601723
    2.5 mg SC weekly titrate to 15 mg • SC • weekly
    trigger: inadequate weight loss response after 6 months
    SURMOUNT-1

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Known resistant HTN (≥3 antihypertensives at max tolerated doses including diuretic, BP still uncontrolled) + obesity (BMI ≥30) + OSA features (witnessed apnea, snoring, daytime sleepiness, morning headache) presenting with SBP ≥180/DBP ≥120 + end-organ damage; Early-morning BP surge + witnessed nocturnal apnea + non-dipping ABPM pattern + resistant HTN despite ≥3 agents; BMI ≥40 (class III obesity) + uncontrolled HTN + cor pulmonale or right-heart strain on echo.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Obesity + obstructive sleep apnea (OSA) hypertensive emergency (resistant-HTN phenotype with sympathetic + RAAS overdrive; CPAP + weight loss + MRA central to long-term control)** (cardio.hypertensive-emergency.obesity-osa-related.v1).
Scope: Obesity + OSA hypertensive crisis = resistant-HTN phenotype crossed crisis threshold. Pathophys: chronic intermittent hypoxemia + arousals → sympathetic + RAAS + endothelial overdrive; ~30% of resistant HTN explained by OSA. Acute: standard HTN-emergency (nicardipine, labetalol). Specialty value: identify + treat OSA acutely (CPAP) + plan long-term resistant-HTN ladder (MRA + thiazide-like + RDN consideration).

No severity triggers fired against current inputs.

Plan

Regimen axis: **Obesity + OSA HTN crisis — acute IV nicardipine + labetalol; CPAP/BiPAP initiation; long-term PATHWAY-2 ladder (MRA + thiazide-like) + GLP-1 RA + bariatric surgery + renal denervation as adjunct**.
1. nicardipine 5 mg/h IV titrate q5-15 min by 2.5 mg/h, max 15 mg/h IV continuous infusion (dihydropyridine_ccb, first line) — AHA 2025 HTN emergency Class I — first-line non-dissection adult HTN crisis; predictable titration, minimal reflex tachycardia
2. labetalol 10-20 mg IV q10 min titrate to SBP <160 (max 300 mg cumulative); OR 0.5-2 mg/min infusion IV PRN bolus or continuous (mixed_alpha_beta_blocker, first line) — AHA 2025 — mixed α/β useful in OSA-driven sympathetic crisis; addresses both vasoconstriction and tachycardia
3. nitroglycerin 5-200 mcg/min IV titrate q3-5 min IV continuous (organic_nitrate, second line) — Vasodilator + venodilator + coronary vasodilator; useful when LV-failure/pulm-edema overlay present (common in obesity-OSA HFpEF)
4. spironolactone 25 mg PO daily, titrate to 50 mg PO daily (mineralocorticoid_receptor_antagonist, first line) — PATHWAY-2 (Williams Lancet 2015 PMID 26414968) — spironolactone superior to doxazosin and bisoprolol as 4th-line agent for resistant HTN; effect amplified in OSA + PA-enriched populations
5. chlorthalidone 12.5-25 mg PO daily PO daily (thiazide_like_diuretic, first line) — Thiazide-like preferred over HCTZ for resistant HTN (longer half-life, better 24-h BP control); PATHWAY-2 + ALLHAT
6. amlodipine 5-10 mg PO daily PO daily (dihydropyridine_ccb, first line) — CCB pillar of standard 3-drug + MRA resistant-HTN regimen (ACC/AHA 2025)
7. lisinopril 10-40 mg PO daily PO daily (ace_inhibitor, first line) — RAAS-blockade pillar; particularly useful in obesity-OSA where RAAS activation is mechanistic
8. semaglutide 0.25 mg SC weekly × 4 wk → 0.5 mg × 4 wk → 1 mg × 4 wk → 1.7 mg → 2.4 mg SC weekly maintenance SC weekly (glp1_receptor_agonist, add on) — STEP-1 (Wilding NEJM 2021 PMID 33567185) ~15% weight loss; STEP-HFpEF (Kosiborod NEJM 2023 PMID 37877559) cardiometabolic benefit in obesity-related HFpEF; secondary BP reduction via weight loss
9. tirzepatide 2.5 mg SC weekly × 4 wk titrate q4 wk to max 15 mg SC weekly (dual_gip_glp1_agonist, add on) — SURMOUNT-1 — superior weight loss to semaglutide; BP reduction signal
10. clonidine 0.1 mg PO BID titrate to 0.3 mg BID; transdermal Catapres-TTS-3 0.3 mg/24h alternative PO + transdermal BID + weekly patch (central_alpha2_agonist, second line) — Add-on if MRA + α-blocker insufficient; AVOID abrupt discontinuation (rebound HTN risk — cross-link clonidine-withdrawal engine)
11. CPAP / BiPAP for OSA / OHS Auto-CPAP 5-15 cmH2O range; titrate to AHI <5 + SpO2 ≥90% across night; BiPAP (IPAP 12-20 / EPAP 6-10) for OHS overlap mask every night ≥4 h/night ≥70% of nights (positive_airway_pressure, first line) — CRESCENDO (Pedrosa 2014 PMID 24571566) + Schein meta-analysis (PMID 25096531) — CPAP reduces 24-h SBP/DBP by ~7/5 mmHg in resistant HTN with OSA; greatest benefit in severe OSA + adherent users
12. Bariatric surgery (RYGB or sleeve gastrectomy) Per surgical evaluation surgical one-time (metabolic_surgery, add on) — Sustained 25-30% weight loss + HTN remission in 50-70%; preferred over medical-only therapy for severe obesity with refractory HTN
13. Renal denervation (RDN) Bilateral renal artery RF or US ablation per SPYRAL/RADIANCE protocol endovascular one-time (device_based_therapy, add on) — SPYRAL HTN-OFF MED (Böhm Lancet 2020 PMID 32562445) — sustained ~10/5 mmHg reduction; FDA-approved 2023 for adjunctive use
14. Weight loss + DASH diet + exercise Target 5-10% weight loss; DASH diet; 150 min/week moderate aerobic + 2 sessions resistance lifestyle daily (lifestyle_intervention, first line) — Look AHEAD (Wing NEJM 2013 PMID 23796131) + ACC/AHA 2025 lifestyle recommendation; foundation of all obesity-related HTN management

Setting playbook (outpatient) — Long-term PCP + cardiology + sleep medicine + bariatric medicine coordination — sustained BP <130/80, CPAP adherence, 5-10%+ weight loss, periodic reassessment of resistant-HTN ladder including renal denervation if refractory
15. maintain PATHWAY-2 ladder titrated to BP target PO daily — sustained maintenance (ACC/AHA 2025 + PATHWAY-2)
16. maintain semaglutide 2.4 mg 2.4 mg SC weekly SC weekly — sustained weight management (STEP-1)
17. consider tirzepatide if inadequate semaglutide response 2.5 mg SC weekly titrate to 15 mg SC weekly — inadequate weight loss response after 6 months (SURMOUNT-1)

Non-pharmacologic actions:
- CPAP adherence target ≥4 h/night ≥70% nights with AHI <5 on therapy
- DASH diet maintenance
- Exercise 150 min/week aerobic + 2 sessions resistance
- Bariatric surgery referral if BMI ≥40 refractory after 6-12 months max therapy
- Renal denervation referral if BP refractory after max medical + lifestyle + secondary causes excluded (SPYRAL)

AVOID / contraindication checks:
- Nicardipine_avoid_severe_aortic_stenosis_or_advanced_HF_with_cardiogenic_shock
- Labetalol_avoid_2nd_3rd_degree_AV_block_or_severe_bradycardia
- Spironolactone_avoid_hyperkalemia_K_above_5.5_or_eGFR_below_30
- Thiazide_ineffective_below_eGFR_30_switch_to_loop_or_indapamide
- Semaglutide_avoid_personal_or_family_history_MTC_or_MEN2 (drug label)
- Semaglutide_pause_if_pancreatitis_history_or_severe_GI_intolerance
- Bariatric_surgery_screen_for_psychiatric_stability_and_substance_use
- Renal_denervation_only_after_max_medical_therapy_and_secondary_causes_excluded (SPYRAL)
- CPAP_adherence_4h_night_threshold_for_BP_benefit (Schein meta analysis)

Monitoring

Regimen monitoring:
- continuous ECG q15 30 min BP minimum 24h (AHA 2025 HTN)
- serial troponin q3-6h x2 if chest pain or CAD history
- BMP for K and Cr at baseline 24h 72h then weekly during MRA initiation
- CPAP adherence download at 4 weeks then quarterly (hours/night, AHI on therapy, mask leak)
- weight weekly during GLP1 titration then monthly to assess 5-10 weight loss response
- home BP monitoring 24h ABPM at 3 months to confirm dipping pattern restoration
- aldosterone-renin ratio repeat off interfering meds if initial borderline
- echo at 6-12 months for LVH regression with BP control and CPAP adherence

Setting (outpatient) monitoring:
- Quarterly BP via home BP monitor
- Annual 24-h ABPM
- Annual echo + ECG
- Annual CPAP adherence + repeat HSAT/PSG if symptoms recur

Follow-up plan: Sleep medicine 2-4 weeks post-d/c for CPAP titration + adherence verification; cardiology + nephrology for resistant HTN; endocrine if PA/pheo positive; nutrition + bariatric medicine for weight management (semaglutide titration over 16 weeks; bariatric surgery referral if BMI ≥40 refractory); home BP monitoring (target <130/80 if standard, <125/75 if CKD/DM); CPAP adherence target ≥4 h/night ≥70% of nights with AHI <5 on therapy; weight loss target 5-10% in 6-12 months → reassess HTN regimen; renal denervation referral if BP refractory after maximal medical + lifestyle therapy + secondary causes excluded
- Close-out criterion: CPAP adherence on track + weight management plan active + 4-week PCP/cardiology booked + sleep-medicine follow-up scheduled

Monitoring phase: Continuous ECG + telemetry; q15-30 min BP × 24 h then q1-2h; serial troponin q3-6h × 2 if elevated; nocturnal SpO2 + capnography; CPAP adherence (hours/night via download); daily BMP for K (MRA) + Cr; weight daily; agitation/somnolence assessment for OHS

Disposition

Current setting: outpatient — Long-term PCP + cardiology + sleep medicine + bariatric medicine coordination — sustained BP <130/80, CPAP adherence, 5-10%+ weight loss, periodic reassessment of resistant-HTN ladder including renal denervation if refractory

Disposition criteria:
- Long-term continuation; cross-link to cardio.htn.resistant.v1 + cardio.hf.hfpef.v1 for chronic management

Escalation triggers (move to higher acuity):
- BP refractory despite max medical + lifestyle + CPAP + secondary causes excluded → renal denervation referral
- New cardiac symptoms → urgent cardiology + echo
- CPAP non-adherence chronic → sleep medicine for alternative therapy (oral appliance, hypoglossal nerve stimulator, ENT for upper-airway surgery)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Severe OSA (AHI >30) + cor pulmonale (RV strain on echo) + RV failure presenting with HTN crisis and hypoxemic respiratory failure
- [SEVERE] Patient with documented severe OSA on CPAP but adherence <4 h/night → recurrent HTN crisis events; failure of long-term BP control
- [SEVERE] Severe GI intolerance (intractable nausea/vomiting, dehydration, AKI) OR acute pancreatitis on semaglutide titration → halt drug + supportive care

Citations

- 2025 ACC/AHA HTN Guideline (Whelton) + AASM 2017 OSA (Kapur PMID 28162150) + PATHWAY-2 (Williams Lancet 2015 PMID 26414968) + STEP-HFpEF (Kosiborod NEJM 2023 PMID 37877559) [PMID:24571566](https://pubmed.ncbi.nlm.nih.gov/24571566/)
- Cited evidence (PMID 28162150) [PMID:28162150](https://pubmed.ncbi.nlm.nih.gov/28162150/)
- Cited evidence (PMID 37877559) [PMID:37877559](https://pubmed.ncbi.nlm.nih.gov/37877559/)
- Cited evidence (PMID 33567185) [PMID:33567185](https://pubmed.ncbi.nlm.nih.gov/33567185/)
- Cited evidence (PMID 26414968) [PMID:26414968](https://pubmed.ncbi.nlm.nih.gov/26414968/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2025 ACC/AHA HTN Guideline (Whelton) + AASM 2017 OSA (Kapur PMID 28162150) + PATHWAY-2 (Williams Lancet 2015 PMID 26414968) + STEP-HFpEF (Kosiborod NEJM 2023 PMID 37877559) — PMID:24571566
  • Cited evidence (PMID 28162150) — PMID:28162150
  • Cited evidence (PMID 37877559) — PMID:37877559
  • Cited evidence (PMID 33567185) — PMID:33567185
  • Cited evidence (PMID 26414968) — PMID:26414968